We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Decitabine: In Myelodysplastic Syndromes.
- Authors
McKeage, Kate; Croom, Katherine F.
- Abstract
▴ Decitabine is a hypomethylating agent. Its action in DNA leads to the reactivation of tumour suppressor genes and the subsequent differentiation of cancer cells.▴ In a randomised, phase III trial in patients (n = 170) with myelodysplastic syndromes (MDS), intravenous decitabine (45 mg/m/day for 3 consecutive days every 6 weeks) combined with supportive care achieved a higher response rate (including eight complete and seven partial responses) than supportive care alone, which achieved no responses (17% vs 0%; p < 0.001).▴ The median times to response and duration of response were 3.3 and 10.3 months in the phase III trial.▴ In three phase II studies in patients (n = 29–87) with MDS treated with decitabine (40 or 50 mg/m/day for 3 days every 5–6 weeks), the percentage of patients achieving a complete or partial response or an improvement ranged from 26% to 49%, and the median duration of response or improvement ranged from 4.9 to 8.3 months.▴ The main adverse event associated with decitabine is myelosuppression.(Table is included in full-text article.)(Figure is included in full-text article.)
- Subjects
TUMOR suppressor genes; CANCER genetics; CANCER cells; MYELODYSPLASTIC syndromes; BREAST cancer; FIBROCYSTIC breast disease; PACLITAXEL; ANTINEOPLASTIC agents; TUMORS; RESEARCH
- Publication
Drugs, 2006, Vol 66, Issue 7, p951
- ISSN
0012-6667
- Publication type
Article
- DOI
10.2165/00003495-200666070-00011